Century Therapeutics (NASDAQ:IPSC) Given New $2.00 Price Target at HC Wainwright

Century Therapeutics (NASDAQ:IPSC) had its price target reduced by HC Wainwright from $5.00 to $2.00 in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts also recently issued research reports about the company. Chardan Capital cut their price objective on Century Therapeutics from $11.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 24th. Piper Sandler decreased their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research report on Thursday, March 20th. Finally, Guggenheim restated a “buy” rating on shares of Century Therapeutics in a report on Friday, March 28th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $4.40.

Century Therapeutics Stock Down 2.3 %

Shares of Century Therapeutics stock opened at $0.46 on Thursday. The business has a fifty day simple moving average of $0.67 and a 200-day simple moving average of $1.10. Century Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $4.43. The firm has a market cap of $39.49 million, a price-to-earnings ratio of -0.25 and a beta of 1.75.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The company had revenue of $4.18 million during the quarter, compared to analyst estimates of $0.67 million. Analysts anticipate that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of IPSC. Geode Capital Management LLC boosted its holdings in shares of Century Therapeutics by 3.5% during the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after purchasing an additional 32,614 shares during the period. Barclays PLC lifted its position in Century Therapeutics by 283.6% in the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after buying an additional 45,797 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Century Therapeutics by 257.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock valued at $123,000 after buying an additional 51,664 shares during the period. State Street Corp grew its holdings in shares of Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after acquiring an additional 57,323 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Century Therapeutics in the third quarter worth $284,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.